Welcome to our dedicated page for WW International news (Ticker: WW), a resource for investors and traders seeking the latest updates and insights on WW International stock.
WW International, Inc. (WeightWatchers), trading under the symbol WW, is frequently in the news for developments in science-backed weight management, clinical programs, and digital health innovation. Company announcements emphasize its role as a global leader in weight health, combining behavioral programs, clinical care, GLP‑1 medications when appropriate, and technology-enabled support.
News about WeightWatchers often covers updates to its integrated GLP‑1 platform, including the WeightWatchers Med+ program and the GLP‑1 Success behavioral support experience. Releases have highlighted access to FDA‑approved GLP‑1 treatments, such as an oral formulation of Wegovy, and the company’s positioning as a NovoCare Recognized Care Provider. These stories focus on how WeightWatchers pairs medication access with evidence‑based nutrition, coaching, and community to improve outcomes.
Investors and observers will also find coverage of new product and feature launches within the WeightWatchers app, such as the Weight Health Score, AI Body Scanner, fitness content partnerships, and configurable Modes that adjust support as members move from weight loss to maintenance. Additional news items include the launch of specialized programs like WeightWatchers for Menopause, the publication of WeightWatchers for Business annual results, collaborations with partners like Amazon Pharmacy, and the introduction of the WeightWatchers Awards for health and wellness products.
On this news page, readers can track earnings announcements, conference participation, leadership appointments, and strategic initiatives related to WeightWatchers’ transformation in the GLP‑1 era. For those following WW stock or the broader weight health sector, the news feed provides a centralized view of how the company is evolving its behavioral and clinical businesses, expanding partnerships, and refining its global weight management platform.
WeightWatchers (NASDAQ: WW) has announced the addition of compounded semaglutide to its weight management program, starting at $129. This expansion aims to enhance accessibility and affordability of weight loss medications amid ongoing shortages of branded GLP-1 drugs. The company's offering combines clinical interventions with behavioral support, including access to board-certified clinicians, registered dietitians, and the WeightWatchers community.
Key points:
- WeightWatchers partnered with an FDA-registered 503B facility to ensure quality and safety
- The company conducted nearly 3 million stock checks, finding GLP-1 medications in stock only 4.5% of the time
- 45% of eligible WeightWatchers Clinic members were denied insurance coverage for GLP-1 medications
- Members using GLP-1 medications with the Points® Program lose 11% more weight than those using medications alone
- Compounded semaglutide will be available to eligible members within 1-3 business days
WeightWatchers (NASDAQ: WW) announced a significant leadership change on Sept. 27, 2024. Tara Comonte, an independent board member, has been appointed as Interim Chief Executive Officer, succeeding Sima Sistani, who is stepping down from her roles as CEO and board member.
During her tenure, Sistani led the company's transformation into a modern digital health organization and expanded its portfolio with the acquisition of Sequence (now WeightWatchers Clinic). Comonte, with her extensive executive leadership experience, is expected to guide the company's transformation, sharpen its strategic focus, and evolve its offerings to drive growth.
The company reaffirmed its full-year 2024 guidance for End of Period Subscribers, Revenue, Adjusted Operating Income, and Adjusted EBITDAS. The WeightWatchers Board of Directors has been reduced from nine to eight members following this transition.
WeightWatchers (NASDAQ: WW) has announced two strategic leadership appointments to drive growth and community engagement. Scott Honken joins as Chief Commercial Officer, overseeing B2B growth, operations, partnerships, and licensing. Phillip Picardi becomes Chief Impact Officer, focusing on building communities and scaling the company's impact work.
Honken, formerly at Calibrate, brings experience from Rightway and Livongo in forming multimillion-dollar partnerships. Picardi, previously Chief Strategy Officer at the Los Angeles LGBT Center, will lead brand marketing, communications, social impact, and employee experience teams.
These appointments align with WeightWatchers' goal to expand access to equitable care and redefine community engagement across all stakeholders, including employers, payers, and health plans.
WW International, Inc. (NASDAQ: WW) announced its Q2 2024 financial results. The company reported revenues of $202.1 million, down 10.9% YoY, with a gross margin of 67.9%. Operating income rose 36.5% to $35.9 million, while adjusted operating income increased 12% to $37.9 million. However, net income dropped 54.2% to $23.3 million, and EPS fell 54.9% to $0.29. End of period subscribers declined 6.1%, with Digital subscribers and Workshops + Digital subscribers decreasing by 4.2% and 21.4%, respectively. The company launched a 2024 restructuring plan to save $100 million annually through operational optimization.
For 2024, WW expects revenues of at least $770 million and adjusted operating income of at least $100 million.
WW International, Inc. (NASDAQ: WW), also known as WeightWatchers, has announced its upcoming second quarter 2024 earnings release and conference call. The company will disclose its Q2 2024 results before the market opens on Thursday, August 1, 2024. Following this, WeightWatchers will host a conference call at 8:30 a.m. ET on the same day.
During the call, CEO Sima Sistani and CFO Heather Stark will discuss the quarterly results and address questions from investors. The event will be accessible via a live webcast on the company's corporate website, where supplemental investor materials will also be available. A replay of the webcast will remain accessible for approximately 90 days after the event.
WW International, Inc. announced its Q1 2024 results, with 4.0 million subscribers and $206.5 million in revenues. The company reported a gross margin of 66.7%, operating loss of $269.3 million due to non-cash intangible impairment charges, and provided full-year guidance. End of period subscribers were down 0.4% year-over-year, while digital subscribers increased by 0.7%. Gross profit was $137.8 million, with adjusted gross profit at $140.3 million. Operating loss was $269.3 million but adjusted to $5.6 million. Net loss was $347.9 million, and the company had a cash balance of $66.6 million as of March 30, 2024.
WeightWatchers for Business has partnered with Personify Health to offer employers integrated access to WeightWatchers' full-spectrum weight health platform. This collaboration aims to provide customizable weight health solutions for organizations using Personify Health's personalized health platform, offering a range of interventions from behavioral to medical for users based on clinical needs. The partnership combines WeightWatchers' science-backed programs with Personify Health's comprehensive health ecosystem to address weight health care needs effectively.
WeightWatchers, known as WW International, Inc., is hosting a live virtual event with Oprah Winfrey on May 9, focusing on a new approach to weight. The event will feature guests like Rebel Wilson and leading medical experts to challenge diet culture and promote a healthier relationship with weight. Participants can register in advance to join the conversation.
Summary not available.
Summary not available.